France With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination for international investments, France is looking to boost innovation, attracting the largest number of R&D centres in Europe in 2022,…
France France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has demonstrated its willingness to take steps towards levelling its pricing barometers and in so doing tackle medicine shortages and build…
USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…
USA With COVID-19 having wreaked havoc on global operations, the pharma industry is understandably focused on leveraging its collective resources and knowhow in discovering and delivering prophylactics and therapeutics against the novel coronavirus. However, even as great strides have been made on that front, companies have to continue delivering their existing…
USA French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic is not without challenges, LFB USA CEO Jose Antonio Moreno Toscano is optimistic that the launches will be a success…
USA Three US country managers for European pharma mid-caps explain the challenges in setting up an American affiliate, as well as how best to capitalise on the abundant opportunities in the world’s biggest pharma market. For Jorge Alderete, president Americas & SVP commercial operations at Danish firm ALK, “Market access…
USA Jose Antonio Moreno Toscano, CEO for the US affiliate of iconic French firm LFB shares the company’s journey in the US market and his insights for other European mid-caps looking to achieve success across the Atlantic. The US market is not really a country market but a continental or…
Belgium Romuald Gaudefroy, managing director of CAF-DCF, the Belgian subsidiary of the LFB Group, introduces the company which was integrated into LFB in 2016. Gaudefroy goes on to offer insights on how a national tender in 2018 has impacted the company’s historic positioning as a manufacturer and also delivers a message…
France Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB. My vision is that we should be strong enough to assume a leadership position in any space that we seek to participate in During his two terms at…
LFB In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the objectives? On April 2010, the sanofi-aventis group and the LFB group have signed a partnership agreement in France and are…
See our Cookie Privacy Policy Here